APA
Click to copy
Williams, C. B., Nebhan, C., Yang, J., Starnes, L., Yan, C., Vilgelm, A., … Richmond, A. (2020). Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy. Breast Cancer Research and Treatment.
Chicago/Turabian
Click to copy
Williams, C. B., C. Nebhan, Jinming Yang, L. Starnes, Chi Yan, A. Vilgelm, Sheau-Chiann Chen, et al. “Correlative Studies Investigating Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer: Potential Implications for Immunotherapy.” Breast Cancer Research and Treatment (2020).
MLA
Click to copy
Williams, C. B., et al. “Correlative Studies Investigating Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer: Potential Implications for Immunotherapy.” Breast Cancer Research and Treatment, 2020.
BibTeX Click to copy
@article{c2020a,
title = {Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy},
year = {2020},
journal = {Breast Cancer Research and Treatment},
author = {Williams, C. B. and Nebhan, C. and Yang, Jinming and Starnes, L. and Yan, Chi and Vilgelm, A. and Chen, Sheau-Chiann and Ayers, G. Dan and Abramson, V. and Mayer, I. and Richmond, A.}
}
Patients with localized breast cancer have a 5-year survival rate > 99% compared to patients with metastatic breast cancer (MBC) that have a 5-year survival rate of ~ 27%. Unregulated PI3K/AKT signaling is a common characteristic of MBC, making it a desirable therapeutic target for tumors with activating mutations in this pathway. Interestingly, inhibition of the PI3K/AKT pathway can affect signaling in immune cells, which could potentially alter the immune phenotype of patients undergoing therapy with these drugs. The purpose of this study is to evaluate how PI3K inhibition affects the immune cells of MBC patients during treatment. We investigated the effects of PI3K inhibition on the immune cell populations in peripheral blood of MBC patients enrolled in 4 different clinical trials utilizing PI3K inhibitors. Peripheral blood was drawn at different points in patient treatment cycles to record immune cell fluctuations in response to therapy. MBC patients who responded to treatment with a positive fold-change in cytotoxic T cell population, had an average duration of treatment response of 31.4 months. In contrast, MBC patients who responded to treatment with a negative fold-change in cytotoxic T-cell population, had an average duration of therapeutic response of 5 months. These data suggest that patients with a more robust, initial anti-tumor T cell response may have a longer therapeutic response compared to patients who do not have a robust, initial anti-tumor T cell response. These results highlight the potential for PI3K inhibition to sensitize tumors to immune checkpoint inhibitors, thus providing additional therapeutic options for patients with MBC.
